Key result
Catheter ablation for drug-refractory paroxysmal atrial fibrillation achieved a single-procedure success rate of 58.7% and a multiprocedure success rate of 86.9% at 12 years.
Why the study?
Does catheter ablation provide long-term success in patients with drug-refractory paroxysmal atrial fibrillation?
Cohort (n=513)
Does catheter ablation provide long-term success in patients with drug-refractory paroxysmal atrial fibrillation?
Answers are grounded in this paper and cite their sources.
Catheter ablation for drug-refractory paroxysmal atrial fibrillation provides a high multiprocedure success rate of 86.9% over a 12-year follow-up, though single-procedure success is modest at 58.7%.
I t is clear that the global burden of atrial fibrillation (AF) and its associated economic footprint in terms of healthcare utilization is rising exponentially. 1 Cumulative evidence suggests that catheter ablation is superior to antiarrhythmic drugs in the management of paroxysmal and persistent AF in terms of improved quality of life, AF-free survival, and AF burden. 2 It is hoped that catheter ablation may ultimately provide a longlasting cure, at least in patients with paroxysmal AF (PAF).Despite this desire, the published literature on long-term outcomes, 3 to 6 years after pulmonary vein isolation (PVI) have reported only a modest single procedural efficacy of ≈50% in the absence of antiarrhythmic drugs. 3,4n this context, the report by Gokoglan et al 5 provides a timely opportunity for a discussion on the progress of catheter ablation of PAF.Uniquely, this is the first study of its kind that reports more than a decade of follow-up of 513 patients with drug-refractory PAF who underwent catheter ablation between 2000 and 2002 (time period chosen to allow 12-year follow-up).The authors report a single-procedure success rate of 58.7% at 12 years and a multiprocedure success rate of 86.9% after a mean of 1.4±0.6 procedures per patient.Of the patients with AF recurrence, approximately three quarters (156 patients) had a repeat procedure.The majority (118 patients or 76% of the reablation cohort) underwent 2 ablation procedures (including the index ablation), 32 (20.1%) patients underwent 3 procedures, and 6 (3.8%) patients required 4 ablation procedures.During the second procedure, the mechanism of AF recurrence was attributed to PV reconnection in 31% and non-PV triggers in the remaining 69% of patients.In patients in whom non-PV triggers were successfully identified, the majority were identified in the coronary sinus (59% of all non-PV triggers), crista terminalis (22%), interatrial septum (17%), superior vena cava (13%), and the left atrial appendage (10%).Notably, no patient had PV conduction recovery beyond the second procedure.Indeed, the mechanism of AF recurrence was surmised to be new non-PV triggers in 92% of patients in the third procedure (8% because of previously identified non-PV triggers) and new non-PV triggers in all 6 patients in the fourth procedure.New sites for non-PV triggers were identified from left atrial appendage (73%), coronary sinus (58%), and interatrial septum (13%).Some insightful data on the timing of AF recurrence were also reported.In patients who were AF free after 2 years and went on to experience a recurrence, just over one half experienced recurrence between 6 and 12 years, one third between 6 and 8 years and the remainder in 4 and 5 years after the index ablation.Importantly, age ≥64 years, left atrial (LA) diameter, female sex, and obesity (body mass index ≥30) were independently associated with AF recurrence.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2016) conducted a cohort in Paroxysmal Atrial Fibrillation (n=513). Catheter ablation was evaluated on Single-procedure success rate. Catheter ablation for drug-refractory paroxysmal atrial fibrillation achieved a single-procedure success rate of 58.7% and a multiprocedure success rate of 86.9% at 12 years.
Synapse has enriched 10 related papers. Consider them for comparative context: